The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
A Controlled Trial of Long-Term Inhaled Hypertonic Saline in Patients with Cystic Fibrosis
Open accessAbstract
BACKGROUND: Inhaled hypertonic saline acutely increases mucociliary clearance and, in short-term trials, improves lung function in people with cystic fibrosis. We tested the safety and efficacy of inhaled hypertonic saline in a long-term trial. METHODS: In this double-blind, parallel-group trial, 164 patients with stable cystic fibrosis who were at least six years old were randomly assigned to inhale 4 ml of either 7 percent hypertonic saline or 0.9 percent (control) saline twice daily for 48 weeks, with quinine sulfate (0.25 mg per milliliter) added to each solution to mask the taste. A bronchodilator was given before each dose, and other standard therapies were continued during the trial. RESULTS: The primary outcome measure, the rate of change (slope) in lung function (reflected by the forced vital capacity [FVC], forced expiratory volume in one second [FEV1], and forced expiratory flow at 25 to 75 percent of FVC [FEF25-75]) during the 48 weeks of treatment, did not differ significantly between groups (P=0.79). However, the absolute difference in lung function between groups was significant (P=0.03) when averaged across all post-randomization visits in the 48-week treatment period. As compared with the control group, the hypertonic-saline group had significantly higher FVC (by 82 ml; 95 percent confidence interval, 12 to 153) and FEV1 (by 68 ml; 95 percent confidence interval, 3 to 132) values, but similar FEF25-75 values. The hypertonic-saline group also had significantly fewer pulmonary exacerbations (relative reduction, 56 percent; P=0.02) and a significantly higher percentage of patients without exacerbations (76 percent, as compared with 62 percent in the control group; P=0.03). Hypertonic saline was not associated with worsening bacterial infection or inflammation. CONCLUSIONS: Hypertonic saline preceded by a bronchodilator is an inexpensive, safe, and effective additional therapy for patients with cystic fibrosis. (ClinicalTrials.gov number, NCT00271310.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Littell, R. C. (1996) · Medical Entomology and Zoology · Cited by 10,547
Clinical Trials: A Practical Approach.
Hill, I. D., & Pocock, S. J. (1984) · Biometrics · doi:10.2307/2531186 · Cited by 2,930
Fuchs, H. J., Borowitz, D. S., Christiansen, D. H., Morris, E. M., Nash, M. L., Ramsey, B. W., Rosenstein, B. J., Smith, A. L., & Wohl, M. E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409083311003 · Cited by 1,539
Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis
Ramsey, B. W., Pepe, M. S., Quan, J. M., Otto, K. L., Montgomery, A. B., Williams-Warren, J., Vasiljev-K, M., Borowitz, D., Bowman, C. M., Marshall, B. C., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901073400104 · Cited by 1,300
Matsui, H., Grubb, B. R., Tarran, R., Randell, S. H., Gatzy, J. T., Davis, C. W., & Boucher, R. C. (1998) · Cell · doi:10.1016/s0092-8674(00)81724-9 · Cited by 1,169
Human β-Defensin-1 Is a Salt-Sensitive Antibiotic in Lung That Is Inactivated in Cystic Fibrosis
Goldman, M. J., Anderson, G. M., Stolzenberg, E. D., Kari, U. P., Zasloff, M., & Wilson, J. M. (1997) · Cell · doi:10.1016/s0092-8674(00)81895-4 · Cited by 1,080
Cystic Fibrosis Airway Epithelia Fail to Kill Bacteria Because of Abnormal Airway Surface Fluid
Smith, J. J., Travis, S. M., Greenberg, E. P., & Welsh, M. J. (1996) · Cell · doi:10.1016/s0092-8674(00)81099-5 · Cited by 1,039
Structure and Function of the CFTR Chloride Channel
SHEPPARD, D. N., & WELSH, M. J. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.1.s23 · Cited by 1,018
Cited by
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105185 · Cited by 2,195
Airway Mucus Function and Dysfunction
Fahy, J. V., & Dickey, B. F. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0910061 · Cited by 1,722
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
Wainwright, C. E., Elborn, J. S., Ramsey, B. W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., Davies, J. C., De Boeck, K., Flume, P. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409547 · Cited by 1,622
Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
Brooke, J. S. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-11 · Cited by 1,434
O'Sullivan, B. P., & Freedman, S. D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60327-5 · Cited by 1,320
Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health
Flume, P. A., O'Sullivan, B. P., Robinson, K. A., Goss, C. H., Mogayzel, P. J., Willey-Courand, D. B., Bujan, J., Finder, J., Lester, M., Quittell, L., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-664oc · Cited by 1,024
The future of cystic fibrosis care: a global perspective
Bell, S. C., Mall, M. A., Gutierrez, H., Macek, M., Madge, S., Davies, J. C., Burgel, P.-R., Tullis, E., Castaños, C., Castellani, C., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30337-6 · Cited by 974
International consensus statement on allergy and rhinology: rhinosinusitis 2021
Orlandi, R. R., Kingdom, T. T., Smith, T. L., Bleier, B., DeConde, A., Luong, A. U., Poetker, D. M., Soler, Z., Welch, K. C., Wise, S. K., et al. (2021) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22741 · Cited by 959
International Consensus Statement on Allergy and Rhinology: Rhinosinusitis
Orlandi, R. R., Kingdom, T. T., Hwang, P. H., Smith, T. L., Alt, J. A., Baroody, F. M., Batra, P. S., Bernal‐Sprekelsen, M., Bhattacharyya, N., Chandra, R. K., et al. (2016) · International Forum of Allergy & Rhinology · doi:10.1002/alr.21695 · Cited by 892
Mucus Clearance and Lung Function in Cystic Fibrosis with Hypertonic Saline
Donaldson, S. H., Bennett, W. D., Zeman, K. L., Knowles, M. R., Tarran, R., & Boucher, R. C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa043891 · Cited by 694
Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health
Mogayzel, P. J., Naureckas, E. T., Robinson, K. A., Mueller, G., Hadjiliadis, D., Hoag, J. B., Lubsch, L., Hazle, L., Sabadosa, K., Marshall, B., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201207-1160oe · Cited by 615
CFTR Function and Prospects for Therapy
Riordan, J. R. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142532 · Cited by 610
Physicochemical properties of mucus and their impact on transmucosal drug delivery
Leal, J., Smyth, H. D. C., & Ghosh, D. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.09.018 · Cited by 560
Ratjen, F., Bell, S. C., Rowe, S. M., Goss, C. H., Quittner, A. L., & Bush, A. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.10 · Cited by 546
Airway Surface Dehydration in Cystic Fibrosis: Pathogenesis and Therapy
Boucher, R. C. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.071905.105316 · Cited by 512
Boyle, M. P., Bell, S. C., Konstan, M. W., McColley, S. A., Rowe, S. M., Rietschel, E., Huang, X., Waltz, D., Patel, N. R., & Rodman, D. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70132-8 · Cited by 452
Progress in therapies for cystic fibrosis
De Boeck, K., & Amaral, M. D. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)00023-0 · Cited by 451
Exacerbations in cystic fibrosis {middle dot} 1: Epidemiology and pathogenesis
Goss, C. H., & Burns, J. L. (2007) · Thorax · doi:10.1136/thx.2006.060889 · Cited by 445
Innate and Induced Resistance Mechanisms of Bacterial Biofilms
Anderson, G. G., & O'Toole, G. A. (2008) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-540-75418-3_5 · Cited by 438
“In particular, aerosolized tobramycin, and more recently nebulized hypertonic saline, have achieved clinical efficacy in treating P. aeruginosa lung infection in patients with cystic fibrosis (Donaldson et al. 2006; Elkins et al. 2006; Gibson et al. 2003).”
BackgroundQuittner, A. L., Modi, A. C., Wainwright, C., Otto, K., Kirihara, J., & Montgomery, A. B. (2009) · Chest · doi:10.1378/chest.08-1190 · Cited by 400
Muco-Obstructive Lung Diseases
Boucher, R. C. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1813799 · Cited by 398
Physiology and pathophysiology of human airway mucus
Hill, D. B., Button, B., Rubinstein, M., & Boucher, R. C. (2022) · Physiological Reviews · doi:10.1152/physrev.00004.2021 · Cited by 366
Evidence for airway surface dehydration as the initiating event in CF airway disease
Boucher, R. C. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01744.x · Cited by 356
Kerem, E., Konstan, M. W., De Boeck, K., Accurso, F. J., Sermet-Gaudelus, I., Wilschanski, M., Elborn, J. S., Melotti, P., Bronsveld, I., Fajac, I., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70100-6 · Cited by 346
Grasemann, H., & Ratjen, F. (2023) · New England Journal of Medicine · doi:10.1056/nejmra2216474 · Cited by 334
Effective mucus clearance is essential for respiratory health
Randell, S. H., & Boucher, R. C. (2006) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2006-0082sf · Cited by 335
Ong, T., & Ramsey, B. W. (2023) · JAMA · doi:10.1001/jama.2023.8120 · Cited by 315
Davies, J. C., Alton, E. W. F. W., & Bush, A. (2007) · BMJ · doi:10.1136/bmj.39391.713229.ad · Cited by 306
Managing Cystic Fibrosis: Strategies That Increase Life Expectancy and Improve Quality of Life
Cohen-Cymberknoh, M., Shoseyov, D., & Kerem, E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201009-1478ci · Cited by 287
Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic Fibrosis
Retsch-Bogart, G. Z., Quittner, A. L., Gibson, R. L., Oermann, C. M., McCoy, K. S., Montgomery, A. B., & Cooper, P. J. (2009) · Chest · doi:10.1378/chest.08-1421 · Cited by 281
Cystic fibrosis: a disease of vulnerability to airway surface dehydration
Boucher, R. C. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.05.001 · Cited by 273
Heijerman, H., Westerman, E., Conway, S., & Touw, D. (2009) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2009.04.005 · Cited by 264
Clunes, L. A., Davies, C. M., Coakley, R. D., Aleksandrov, A. A., Henderson, A. G., Zeman, K. L., Worthington, E. N., Gentzsch, M., Kreda, S. M., Cholon, D., et al. (2012) · The FASEB Journal · doi:10.1096/fj.11-192377 · Cited by 261
CFTR: cystic fibrosis and beyond
Mall, M. A., & Hartl, D. (2014) · European Respiratory Journal · doi:10.1183/09031936.00228013 · Cited by 259
Acidic pH increases airway surface liquid viscosity in cystic fibrosis
Tang, X. X., Ostedgaard, L. S., Hoegger, M. J., Moninger, T. O., Karp, P. H., McMenimen, J. D., Choudhury, B., Varki, A., Stoltz, D. A., & Welsh, M. J. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83922 · Cited by 254
Pulmonary medication adherence and health-care use in cystic fibrosis
Quittner, A. L., Zhang, J., Marynchenko, M., Chopra, P. A., Signorovitch, J., Yushkina, Y., & Riekert, K. A. (2014) · Chest · doi:10.1378/chest.13-1926 · Cited by 250
Cystic Fibrosis Lung Disease: An Overview
Turcios, N. L. (2020) · Respiratory Care · doi:10.4187/respcare.06697 · Cited by 217
Riekert, K. A., Bartlett, S. J., Boyle, M. P., Krishnan, J. A., & Rand, C. S. (2007) · Chest · doi:10.1378/chest.06-2474 · Cited by 197
Wainwright, C. E., France, M. W., O'Rourke, P., Anuj, S., Kidd, T. J., Nissen, M. D., Sloots, T. P., Coulter, C., Ristovski, Z., Hargreaves, M., et al. (2009) · Thorax · doi:10.1136/thx.2008.112466 · Cited by 135
Self-citationLechtzin, N., Mayer-Hamblett, N., West, N. E., Allgood, S., Wilhelm, E., Khan, U., Aitken, M. L., Ramsey, B. W., Boyle, M. P., Mogayzel, P. J., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201610-2172oc · Cited by 127
George, M., Rand-Giovannetti, D., Eakin, M. N., Borrelli, B., Zettler, M., & Riekert, K. A. (2010) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2010.08.016 · Cited by 118
Sanders, D. B., & Fink, A. K. (2016) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2016.04.001 · Cited by 109
Rapid therapeutic advances in CFTR modulator science
Clancy, J. P. (2018) · Pediatric Pulmonology · doi:10.1002/ppul.24157 · Cited by 52
Health-related quality of life in children with cystic fibrosis: validation of the German CFQ-R
Schmidt, A., Wenninger, K., Niemann, N., Wahn, U., & Staab, D. (2009) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-7-97 · Cited by 37
Dawson, S., Girling, C.-J., Cowap, L., & Clark-Carter, D. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013766.pub2 · Cited by 14
Cystic fibrosis – Ten promising therapeutic approaches in the current era of care
Somayaji, R., Nichols, D. P., & Bell, S. C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1805733 · Cited by 12
Metadata
- Authors
- Elkins, M. R., Robinson, M., Rose, B. R., Harbour, C., Moriarty, C. P., Marks, G. B., Belousova, E. G., Xuan, W., & Bye, P. T. P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-01-19
- Volume
- 354
- Issue
- 3
- Pages
- 229-240
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2103043501
- Cited by
- 862
- References
- 29
- FWCI
- 52.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.